Literature DB >> 19545205

Future of polio vaccines.

Ellie Ehrenfeld1, John Modlin, Konstantin Chumakov.   

Abstract

Over the past half-century, global use of highly effective vaccines against poliomyelitis brought this disease to the brink of elimination. Mounting evidence supports the argument that a high level of population immunity must be maintained after wild poliovirus circulation is stopped to preserve a polio-free status worldwide. Shifting factors in the risk-benefit-cost equation favor the creation of new poliovirus vaccines for use in the foreseeable future. Genetically stable attenuated virus strains could be developed for an improved oral poliovirus vaccine, but proving their safety and efficacy would be impractical owing to the enormous size of the clinical trials required. Novel versions of inactivated poliovirus vaccine that could be used globally should be developed. An improved inactivated poliovirus vaccine must be efficacious, inexpensive, safe to manufacture and easy to administer. Combination products containing inactivated poliovirus vaccine and other protective antigens should become part of routine childhood immunizations around the world.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19545205      PMCID: PMC2786268          DOI: 10.1586/erv.09.49

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  42 in total

1.  Emerging concept of poliomyelitis infection.

Authors:  D BODIAN
Journal:  Science       Date:  1955-07-15       Impact factor: 47.728

2.  Cultivation of the Lansing Strain of Poliomyelitis Virus in Cultures of Various Human Embryonic Tissues.

Authors:  J F Enders; T H Weller; F C Robbins
Journal:  Science       Date:  1949-01-28       Impact factor: 47.728

3.  Monovalent type 1 oral poliovirus vaccine in newborns.

Authors:  Nasr el-Sayed; Yehia el-Gamal; Ahmed-Amr Abbassy; Iman Seoud; Maha Salama; Amr Kandeel; Elham Hossny; Ahmed Shawky; Heba Abou Hussein; Mark A Pallansch; Harrie G A M van der Avoort; Anthony H Burton; Meghana Sreevatsava; Pradeep Malankar; Mohamed H Wahdan; Roland W Sutter
Journal:  N Engl J Med       Date:  2008-10-16       Impact factor: 91.245

4.  Social serology; antibody levels in a normal young population during an epidemic of poliomyelitis.

Authors:  J L MELNICK; N LEDINKO
Journal:  Am J Hyg       Date:  1951-11

5.  Acute poliomyelitis relation of physical activity at the time of onset to the course of the disease.

Authors:  D M HORSTMANN
Journal:  J Am Med Assoc       Date:  1950-01-28

6.  Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza.

Authors:  E E Lasch; Y Abed; K Abdulla; A G El Tibbi; O Marcus; M El Massri; R Handscher; C B Gerichter; J L Melnick
Journal:  Rev Infect Dis       Date:  1984 May-Jun

7.  Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world.

Authors:  A B Sabin
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

Review 8.  Polio eradication: the OPV paradox.

Authors:  Walter R Dowdle; Esther De Gourville; Olen M Kew; Mark A Pallansch; David J Wood
Journal:  Rev Med Virol       Date:  2003 Sep-Oct       Impact factor: 6.989

9.  Strategies for elimination of poliomyelitis in different parts of the world with use of oral poliovirus vaccine.

Authors:  A B Sabin
Journal:  Rev Infect Dis       Date:  1984 May-Jun

10.  Effectiveness of immunization against paralytic poliomyelitis in Nigeria.

Authors:  Helen E Jenkins; R Bruce Aylward; Alex Gasasira; Christl A Donnelly; Emmanuel A Abanida; Titi Koleosho-Adelekan; Nicholas C Grassly
Journal:  N Engl J Med       Date:  2008-10-16       Impact factor: 91.245

View more
  16 in total

1.  Delivery strategies for novel vaccine formulations.

Authors:  Maria Trovato; Shelly J Krebs; Nancy L Haigwood; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2012-02-12

Review 2.  Vaccines: the fourth century.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2009-09-30

3.  Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.

Authors:  Zhaochun Chen; Konstantin Chumakov; Eugenia Dragunsky; Diana Kouiavskaia; Michelle Makiya; Alexander Neverov; Gennady Rezapkin; Andrew Sebrell; Robert Purcell
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

4.  A mucosal adjuvant for the inactivated poliovirus vaccine.

Authors:  Benjamin P Steil; Patricia Jorquera; Janny Westdijk; Wilfried A M Bakker; Robert E Johnston; Mario Barro
Journal:  Vaccine       Date:  2013-12-13       Impact factor: 3.641

Review 5.  Systems vaccinology: Enabling rational vaccine design with systems biological approaches.

Authors:  Thomas Hagan; Helder I Nakaya; Shankar Subramaniam; Bali Pulendran
Journal:  Vaccine       Date:  2015-04-06       Impact factor: 3.641

Review 6.  Ubiquitin-independent proteasomal degradation during oncogenic viral infections.

Authors:  Jiwon Hwang; Laura Winkler; Robert F Kalejta
Journal:  Biochim Biophys Acta       Date:  2011-06-06

7.  Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010.

Authors:  Jan Felix Drexler; Gilda Grard; Alexander N Lukashev; Liubov I Kozlovskaya; Sindy Böttcher; Gökhan Uslu; Johan Reimerink; Anatoly P Gmyl; Raphaël Taty-Taty; Sonia Etenna Lekana-Douki; Dieudonné Nkoghe; Anna M Eis-Hübinger; Sabine Diedrich; Marion Koopmans; Eric M Leroy; Christian Drosten
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

8.  Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.

Authors:  Gabriel I Parra; Karin Bok; Ross Taylor; Joel R Haynes; Stanislav V Sosnovtsev; Charles Richardson; Kim Y Green
Journal:  Vaccine       Date:  2012-03-31       Impact factor: 3.641

Review 9.  Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus.

Authors:  Carlo Amorin Daep; Jorge L Muñoz-Jordán; Eliseo Alberto Eugenin
Journal:  J Neurovirol       Date:  2014-10-07       Impact factor: 2.643

10.  Antiviral activity of 3(2H)- and 6-chloro-3(2H)-isoflavenes against highly diverged, neurovirulent vaccine-derived, type2 poliovirus sewage isolates.

Authors:  Lester M Shulman; Danit Sofer; Yossi Manor; Ella Mendelson; Jean Balanant; Anna Laura Salvati; Francis Delpeyroux; Lucia Fiore
Journal:  PLoS One       Date:  2011-05-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.